Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**isopropyl alcohol + dexamethasone sodium phosphate + lidocaine hydrochloride + povidone-iodine** is a multi-component pharmaceutical kit marketed under the brand name **Dexlido**. It combines **dexamethasone sodium phosphate**, a water-soluble synthetic glucocorticoid corticosteroid that activates the **glucocorticoid receptor** to produce anti-inflammatory and immunosuppressive effects, with **lidocaine hydrochloride** for local anesthetic activity, **povidone-iodine** as a topical antiseptic, and **isopropyl alcohol** as a skin disinfectant. Based on the provided context, the therapeutic rationale is centered on dexamethasone sodium phosphate, while the other components support procedural analgesia and antisepsis. Publicly described labeling indicates broad corticosteroid-type indications derived from dexamethasone injection labeling, but the product itself appears to be an **unapproved drug product** whose labeling has **not been approved by the FDA**. The specific developer and manufacturer are not clearly established from the provided materials.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on isopropyl alcohol + dexamethasone sodium phosphate + lidocaine hydrochloride + povidone-iodine.